Clinical Trial Closeup

Potential of low-light therapy for dry AMD

Trial shows effectiveness of the Valeda Light Delivery System photobiomodulation platform.

Reviving dormant photoreceptors in LCA1

The gene therapy ATSN-101 has demonstrated safety and shown signals of efficacy in restoring vision in Leber congenital amaurosis.

A pill to head off worsening of DRSS

A Phase III trial is on deck for the oral Ref-1 inhibitor APX3330 after a Phase IIb study showed a potential benefit.

Axitinib implant shows early potential

Interim results from Phase I trial of OTX-TKI, a bioresorbable hydrogel platform using a tyrosine kinase inhibitor.

Senolytic therapy: ‘Entirely new paradigm’

A look at UBX1325, a small-molecule B-cell inhibitor that targets the proteins senescent cells feed on for survival.

Sustained-release sunitinib comes to retina

A closer look at the extension study of GB-102 for treatment of neovascular age-related macular degeneration.

A potential stem-cell solution for GA

Trial shows safety of a biosynthetic patch inserted in a subretinal bleb in an outpatient procedure.

Targeting headwaters of classical pathway

The IgG antibody fragment ANX007 aims to disrupt the cascade that leads to geographic atrophy at the initiating molecule.

How THR-149 targets alternate pathway

The plasma kallikrein inhibitor is being investigated to treat diabetic macular edema that doesn’t respond to anti-VEGF therapy.

TKI vorolanib implant shows early signal

DAVIO Phase I results of EYP-1901 show reduced treatment burden in age-related macular degeneration.